Compounds > penicillamine cysteine disulfide
Page last updated: 2024-11-08

penicillamine cysteine disulfide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

penicillamine cysteine disulfide: structure in Merck Index, 9th ed, #6881 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID161257
CHEMBL ID3544531
SCHEMBL ID11801814
MeSH IDM0095671

Synonyms (22)

Synonym
penicillamine cysteine
2005-18-7
d-valine, 3-((2-amino-2-carboxyethyl)dithio)-, (r)-
7wdd7k00td ,
cysteine-penicillamine disulfide
penicillamine cysteine disulfide
18840-45-4
unii-7wdd7k00td
SCHEMBL11801814
DTXSID00172190
CHEMBL3544531
penicillamine cysteine disulfide [mi]
alanine, 3,3-dimethyl-3,3'-dithiodi-
d-valine, 3-(((2r)-2-amino-2-carboxyethyl)dithio)-
valine, 3-((l-2-amino-2-carboxyethyl)dithio)-, d-
l-cysteine-d-penicillamine disulfide
(2s)-2-amino-3-[[(2r)-2-amino-2-carboxyethyl]disulfanyl]-3-methylbutanoic acid
d-valine, 3-[[(2r)-2-amino-2-carboxyethyl]dithio]-
(s)-2-amino-3-(((r)-2-amino-2-carboxyethyl)disulfanyl)-3-methylbutanoic acid
Q27268950
(2s)-2-amino-3-{[(2r)-2-amino-2-carboxyethyl]disulfanyl}-3-methylbutanoic acid
(s)-2-amino-3-(((r)-2-amino-2-carboxyethyl)disulfanyl)-3-methylbutanoicacid

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"The pharmacokinetic disposition of D-penicillamine and its major metabolites, penicillamine cysteine disulfide ( PSSC ) and penicillamine disulfide ( PSSP ) has been studied in eight patients with rheumatoid arthritis."( Pharmacokinetics of the major metabolites of D-penicillamine in patients with rheumatoid arthritis.
Butler, M; Carruthers, G; Freeman, D; Harth, M; Rothwell, R; Weir, D, 1984)		0.5
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.88

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.88 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.88)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (8.33%)6.00%
Case Studies1 (8.33%)4.05%
Observational0 (0.00%)0.25%
Other10 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
probenecid
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.. probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.		1.9610benzoic acids;
sulfonamide		uricosuric drug
penicillamine
Penicillamine: 3-Mercapto-D-valine. The most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease.. penicillamine : An alpha-amino acid having the structure of valine substituted at the beta position with a sulfanyl group.		3.66100non-proteinogenic alpha-amino acid;
penicillamine		antirheumatic drug;
chelator;
copper chelator;
drug allergen
penicillin g
Penicillin G: A penicillin derivative commonly used in the form of its sodium or potassium salts in the treatment of a variety of infections. It is effective against most gram-positive bacteria and against gram-negative cocci. It has also been used as an experimental convulsant because of its actions on GAMMA-AMINOBUTYRIC ACID mediated synaptic transmission.. benzylpenicillin : A penicillin in which the substituent at position 6 of the penam ring is a phenylacetamido group.		1.9310penicillin allergen;
penicillin		antibacterial drug;
drug allergen;
epitope
lysine
Lysine: An essential amino acid. It is often added to animal feed.. lysine : A diamino acid that is caproic (hexanoic) acid bearing two amino substituents at positions 2 and 6.. L-lysine : An L-alpha-amino acid; the L-isomer of lysine.		1.9410aspartate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
lysine;
organic molecular entity;
proteinogenic amino acid		algal metabolite;
anticonvulsant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
valine
Valine: A branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.. valine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isopropyl group.. L-valine : The L-enantiomer of valine.		1.9310L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid;
valine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
arginine
Arginine: An essential amino acid that is physiologically active in the L-form.. arginine : An alpha-amino acid that is glycine in which the alpha-is substituted by a 3-guanidinopropyl group.		1.9410arginine;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		biomarker;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical
penicillamine disulfide
penicillamine disulfide: penicillamine metabolite; RN given refers to cpd without isomeric designation; structure in first source		3.2160valine derivative
cystine
[no description available]		2.3420
cysteine
Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3.		3.66100cysteiniumfundamental metabolite
benzylpenicilloic acid
benzylpenicilloic acid: RN given refers to parent cpd. benzylpenicilloic acid : A penicilloic acid where the side-chain N-acyl group is specified as phenylacetyl.		1.9310
concanavalin a
Concanavalin A: A MANNOSE/GLUCOSE binding lectin isolated from the jack bean (Canavalia ensiformis). It is a potent mitogen used to stimulate cell proliferation in lymphocytes, primarily T-lymphocyte, cultures.		1.9610
ConditionIndicatedRelationship StrengthStudiesTrials
Cystinuria
An inherited disorder due to defective reabsorption of CYSTINE and other BASIC AMINO ACIDS by the PROXIMAL RENAL TUBULES. This form of aminoaciduria is characterized by the abnormally high urinary levels of cystine; LYSINE; ARGININE; and ORNITHINE. Mutations involve the amino acid transport protein gene SLC3A1.		02.6530
Adjuvant Arthritis
[description not available]		01.9610
Delayed Hypersensitivity
[description not available]		01.9610
Rheumatoid Arthritis
[description not available]		02.6530
Arthritis, Rheumatoid
A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.		02.6530
Chronic Kidney Failure
[description not available]		01.9610
Kidney Failure, Chronic
The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.		01.9610